Direct Impact

Concepts for which Josh L Plassmeyer has direct influence:

ilc endocrine
lobular breast
baseline neoadjuvant
therapy evaluate
protein expression
postmenopausal women

Prominent publications by Josh L Plassmeyer

KOL-Index: 2 RATIONALE: Currently, adjuvant endocrine therapy often follows a "one-size-fits- all" approach, with most premenopausal women receiving tamoxifen, and most postmenopausal receiving aromatase inhibitor therapy. In current clinical practice, patients with invasive lobular carcinoma are treated no differently than patients with invasive ductal carcinoma based on the void of information specific ...
Known for
Definitive Surgery | 250 Injections | Premenopausal Women | Size Fits-

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172